In addition, a recent study identified ALK5 kinase (or TGFßR1 - transforming growth factor, beta receptor I) and non-canonical androgen receptors as potential targets for ADPKD drug development using a high throughput screening approach based on a zebrafish Pkd2 mutant (using tail curvature as a primary readout) followed by a secondary validation in 3D cyst assays based on MDCKII and a human PKD1 patient-derived cystic cell line (OX161c1) [138]. Here, PKD2 is linked to autosomal dominant polycystic kidney disease.